Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcus Biosciences (RCUS) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Arcus Biosciences (RCUS) over the last 5 years, with Q3 2025 value amounting to $106.5 million.

  • Arcus Biosciences' Shares Outstanding (Diluted Average) rose 1652.08% to $106.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.5 million, marking a year-over-year increase of 1652.08%. This contributed to the annual value of $90.1 million for FY2024, which is 2175.68% up from last year.
  • Per Arcus Biosciences' latest filing, its Shares Outstanding (Diluted Average) stood at $106.5 million for Q3 2025, which was up 1652.08% from $106.5 million recorded in Q2 2025.
  • Arcus Biosciences' Shares Outstanding (Diluted Average)'s 5-year high stood at $106.5 million during Q2 2025, with a 5-year trough of $71.2 million in Q1 2022.
  • Over the past 5 years, Arcus Biosciences' median Shares Outstanding (Diluted Average) value was $74.3 million (recorded in 2021), while the average stood at $82.9 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first plummeted by 270.27% in 2022, then surged by 2445.36% in 2024.
  • Quarter analysis of 5 years shows Arcus Biosciences' Shares Outstanding (Diluted Average) stood at $74.0 million in 2021, then dropped by 2.7% to $72.0 million in 2022, then increased by 2.78% to $74.0 million in 2023, then increased by 21.76% to $90.1 million in 2024, then grew by 18.2% to $106.5 million in 2025.
  • Its last three reported values are $106.5 million in Q3 2025, $106.5 million for Q2 2025, and $98.4 million during Q1 2025.